Charles River And Autobahn Labs Establish Partnership To Accelerate Academic Discoveries Into Novel Therapeutics; Charles River To Make Equity Investment In Autobahn Labs; Chief Scientific Officer Justin Bryans Named To Autobahn's Board Of Directors
Agreement establishes Charles River as the preferred partner for Autobahn Labs. Charles River will make an equity investment in Autobahn. The company will leverage its drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics. Autobahn is a joint venture between Charles River and Bayer.
Benzinga · 1d ago
Look Under The Hood: EFIV Has 10% Upside
NASDAQ · 3d ago
Weekly Report: what happened at CRL last week (0715-0719)?
Weekly Report · 3d ago
ClearBridge Select Strategy Q2 2024 Commentary
ClearBridge Select Strategy Q2 2024 Commentary: Equity leadership narrowed considerably in the second quarter. The S&P 500 Index rose 4.3% for the period, while the small cap Russell 2000 Index advanced 3.3%. The Russell 3000 Growth Index surged 7.8% in the quarter.
Seeking Alpha · 6d ago
Aristotle Capital Small/Mid Cap Equity Q2 2024 Commentary
Seeking Alpha · 07/18 11:40
Press Release: Charles River Laboratories Schedules Second-Quarter 2024 Earnings Release and Conference Call
Dow Jones · 07/16 20:30
Riverwater Sustainable Value Strategy Q2 2024 Commentary
Riverwater Sustainable Value Strategy outperformed its benchmark for the quarter and year-to-date period. Pockets of opportunity exist for small caps supplying AI hyperscalers in chip development and data center construction. We believe there is tremendous opportunity to use AI to improve productivity and growth for companies.
Seeking Alpha · 07/16 16:15
Weekly Report: what happened at CRL last week (0708-0712)?
Weekly Report · 07/15 09:20
Risks To Shareholder Returns Are Elevated At These Prices For Charles River Laboratories International, Inc. (NYSE:CRL)
Charles River Laboratories International, Inc. Has a price-to-earnings ratio of 23.5x. The company's earnings have been falling quicker than most other companies in the U.S. Its P/E ratio is higher than the average for a company of the same size. Charles River Laboratories international is trading on a higher than expected growth rate compared to the market.
Simply Wall St · 07/11 15:14
Apple To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday
Goldman Sachs raised the price target for Tesla, Inc. (NASDAQ:TSLA) on Tuesday. The price target was raised from $175 to $248. Needham boosted the price targets for Apple Inc. And Mastercard. Keybanc lifted the target for Netflix from $707 to $735.
Benzinga · 07/10 13:22
Charles River Labs Price Target Cut to $239.00/Share From $271.00 by Baird
Dow Jones · 07/10 12:25
Charles River Labs Is Maintained at Outperform by Baird
Dow Jones · 07/10 12:25
Baird Maintains Outperform on Charles River, Lowers Price Target to $239
Benzinga · 07/10 12:15
Charles River And AAVantgarde Ink CDMO Contract To Produce Good Manufacturing Practice-Plasmid DNA
Charles River and AAVantgarde announce a contract development and manufacturing agreement to produce GMP plasmid DNA. The DNA will be used for therapeutic targeting high unmet need ophthalmology indication. Charles River will develop the DNA for AAV's Stargardt's disease program.
Benzinga · 07/08 12:11
Weekly Report: what happened at CRL last week (0701-0705)?
Weekly Report · 07/08 09:20
ClearBridge Growth Strategy Q2 2024 Commentary
ClearBridge Growth Strategy outperformed in a difficult period for smaller cap stocks. Russell 3000 Growth Index has become dominated by mega caps. The S&P 500 Index rose 4.28% in the second quarter of 2024. The Russell Midcap Growth Index is the new benchmark for the ClearBridge growth strategy.
Seeking Alpha · 07/06 11:45
Charles River (CRL) Could be an Apt Pick Right Now: Here's Why
NASDAQ · 07/05 13:23
Weekly Report: what happened at CRL last week (0624-0628)?
Weekly Report · 07/01 09:20
Barclays Initiates Coverage of Charles River Laboratories International (CRL) with Equal-Weight Recommendation
NASDAQ · 06/29 06:05
Charles River Labs downgraded at Argus on cautious biotech spending
Argus has downgraded Charles River Laboratories to hold from buy. The firm says the contract research firm is facing headwinds to revenue growth. The stock is down 12% year to date. Argus says the company is facing cautious spending in the biotech industry. Charles River Labs downgraded on cautious biotech spending.
Seeking Alpha · 06/28 17:20
Webull provides a variety of real-time CRL stock news. You can receive the latest news about Charles Riv Labs Intl Inc through multiple platforms. This information may help you make smarter investment decisions.
About CRL
Charles River Laboratories International, Inc. provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. The Company's Research Models and Services segment is comprised of three businesses that provide foundational tools that enables its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.